<p>PureTech Health plc（納斯達克代碼：PRTC - 獲取免費報告）在週一的交易中上漲了 2.5%。該股票最高交易價為$18.53，最後交易價為$18.25。在午盤交易中，約有 3,307 股成交，較日均成交量 2,553 股增加了 30%。該股票此前收盤價為$17.80。</p>
<p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
<h2>PureTech Health 股票上漲 2.5%</h2>
<p>該公司的 50 日簡單移動平均線為$18.55，200 日簡單移動平均線為$20.20。</p>
<h2>機構資金流入與流出</h2>
<p>一家對沖基金最近在 PureTech Health 股票中購買了新股份。根據該公司在最近向 SEC 提交的 13F 文件，Millennium Management LLC 在第四季度購買了 PureTech Health plc（納斯達克代碼：PRTC - 免費報告）的新頭寸。該公司購買了 45,264 股，價值約為$823,000。截至最近的 SEC 文件，Millennium Management LLC 持有 PureTech Health 的 0.19%。機構投資者持有該公司 0.04% 的股份。</p>
<h2>關於 PureTech Health</h2>
<p>（獲取免費報告）</p>
<p>PureTech Health plc 從事生物技術和製藥解決方案的開發和商業化，主要在美國。該公司正在開發 LYT-100，目前處於第二階段，旨在治療特發性肺纖維化（IPF）；以及 LYT-200，一種 IgG4 單克隆抗體，目前處於 1/2 階段，針對 galectin-9 用於治療實體腫瘤和血液惡性腫瘤。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 PureTech Health</li>
<li>如何開始投資便士股票</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求庇護</li>
<li>賣空：如何做空股票</li>
<li>3 只超賣的七隻奇蹟股票處於關鍵水平：現在買入嗎？</li>
<li>市值計算器：如何計算市值</li>
<li>3M 預計在年中達到$175，且更高的高點很可能出現</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 PureTech Health 嗎？</h2>
<p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 PureTech Health 並不在名單上。</p>
<p>雖然 PureTech Health 目前在分析師中獲得了強烈買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRTC

<p>PureTech Health（納斯達克代碼：PRTC）股票在交易中上漲了 2.5%，達到 18.25 美元，成交量顯著增加。對沖基金 Millennium Management LLC 最近收購了 45,264 股，價值約為 82.3 萬美元。該公司專注於開發生物技術解決方案，包括特發性肺纖維化和實體腫瘤的治療。儘管分析師給予了強烈買入評級，但他們建議還有更好的投資選擇</p>

<p>PureTech Health plc (NASDAQ:PRTC - Get Free Report) rose 2.5% during trading on Monday . The stock traded as high as $18.53 and last traded at $18.25. Approximately 3,307 shares traded hands during mid-day trading, an increase of 30% from the average daily volume of 2,553 shares. The stock had previously closed at $17.80.</p>
<div class="lb-trans"><p>PureTech Health plc（納斯達克代碼：PRTC - 獲取免費報告）在週一的交易中上漲了 2.5%。該股票最高交易價為$18.53，最後交易價為$18.25。在午盤交易中，約有 3,307 股成交，較日均成交量 2,553 股增加了 30%。該股票此前收盤價為$17.80。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PureTech Health</strong> 的提醒：</p>
</div><h2>PureTech Health Stock Up 2.5 %</h2>
<div class="lb-trans"><h2>PureTech Health 股票上漲 2.5%</h2>
</div><p>The firm has a 50 day simple moving average of $18.55 and a 200 day simple moving average of $20.20.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為$18.55，200 日簡單移動平均線為$20.20。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>A hedge fund recently bought a new stake in PureTech Health stock. Millennium Management LLC bought a new position in PureTech Health plc (NASDAQ:PRTC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 45,264 shares of the company's stock, valued at approximately $823,000. Millennium Management LLC owned 0.19% of PureTech Health as of its most recent SEC filing. Institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>一家對沖基金最近在 PureTech Health 股票中購買了新股份。根據該公司在最近向 SEC 提交的 13F 文件，Millennium Management LLC 在第四季度購買了 PureTech Health plc（納斯達克代碼：PRTC - 免費報告）的新頭寸。該公司購買了 45,264 股，價值約為$823,000。截至最近的 SEC 文件，Millennium Management LLC 持有 PureTech Health 的 0.19%。機構投資者持有該公司 0.04% 的股份。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>關於 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.</p>
<div class="lb-trans"><p>PureTech Health plc 從事生物技術和製藥解決方案的開發和商業化，主要在美國。該公司正在開發 LYT-100，目前處於第二階段，旨在治療特發性肺纖維化（IPF）；以及 LYT-200，一種 IgG4 單克隆抗體，目前處於 1/2 階段，針對 galectin-9 用於治療實體腫瘤和血液惡性腫瘤。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
<li>How to start investing in penny stocks</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>Short Selling: How to Short a Stock</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 PureTech Health</li>
<li>如何開始投資便士股票</li>
<li>看跌投資者可以在抗衰退 ETF 中尋求庇護</li>
<li>賣空：如何做空股票</li>
<li>3 只超賣的七隻奇蹟股票處於關鍵水平：現在買入嗎？</li>
<li>市值計算器：如何計算市值</li>
<li>3M 預計在年中達到$175，且更高的高點很可能出現</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 PureTech Health 嗎？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 PureTech Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 PureTech Health 並不在名單上。</p>
</div><p>While PureTech Health currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PureTech Health 目前在分析師中獲得了強烈買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

PureTech Health (NASDAQ:PRTC) 股價上漲 2.5% - 接下來會發生什麼？